Futura Medical PLC Block Listing Six Monthly Review
31 May 2024 - 4:00PM
RNS Regulatory News
RNS Number : 5235Q
Futura Medical PLC
31 May 2024
Block Listing Six Monthly Return
31 May 2024
Futura Medical plc (AIM:
FUM), the consumer healthcare company
behind Eroxon, that specialises in the development
and global commercialisation of innovative and clinically
proven sexual health products, makes
the following update on its block listings, pursuant to AIM Rule 29
and Schedule Six of the AIM Rules for Companies. All figures relate
to options over Ordinary Shares of 0.2 pence each (Ordinary
Shares).
Date: 31 May 2024
|
Name of applicant:
|
Futura Medical Plc
|
|
Name of scheme(s):
|
Unapproved Share Option
Scheme
Unapproved Share Incentive
Scheme
EMI Share Option Scheme
LTIP Scheme
|
|
Period of return:
|
From:
|
1 December 2023
|
To:
|
31 May 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
20,782,665
|
|
Plus:
The amount by which the block scheme(s) has been
increased since the date of the last return (if any increase has
been applied for):
|
USOS: nil
USIS: nil
EMI: nil
LTIP: nil
|
|
Less:
Number of securities issued/allotted under
scheme(s) during period:
|
USOS: nil
USIS: nil
EMI: nil
LTIP: nil
|
|
Equals:
Balance under scheme(s) not yet issued/allotted at
end of period:
|
20,782,665
|
|
Number and class of securities
originally admitted and the date of admission
|
USOS Total: 3,882,912
814,424 25 May 2011
1,202,280
8 October 2013
1,466,208
25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI
Total: 8,112,088
1,520,576
25 May 2011
1,467,720
8 October 2013
1,893,792
25 May 2017
790,000 30 May 2018
1,340,000
30 November 2018
1,100,000
2 February 2023
LTIP Total: 15,035,617
4,444,942
2 February 2023
10,590,675
3 November 2023
|
|
|
|
|
| |
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Liberum
Nominated Adviser
and Broker
|
Phil Walker
Richard Lindley
Nikhil Varghese
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRAMMATMTMJBFI
Futura Medical (LSE:FUM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From Sep 2023 to Sep 2024
